Health system under pressure: sustainability as a lever for prevention

At WeACT Con, experts discussed how prevention and environmental health can reduce risks and help stabilize healthcare, from funding ideas to guidance.

Bedrocan flower to be offered as Becanex PIEX raw extract for compounding

Bedrocan and Becanex plan PIEX Bedrocan 70% THC as a raw extract for pharmacy compounding, with shipments expected to start in summer 2026.

Vetter breaks ground on new production site in Saarlouis

Vetter has started construction of a new production site in Saarlouis. The first phase includes a 50,000 m² building, with start-up planned for 2031.

Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1bn

Angelini Pharma has agreed to buy Catalyst for $4.1bn in cash, entering the U.S. market. The companies expect the deal to close in Q3 2026.

UEFA appoints Haleon as first medicine and health partner

UEFA has named Haleon its first partner for medicine and health. The multi-year collaboration focuses on evidence-based pain management in football.

Daiichi Sankyo honors patient initiatives with O-Mamori Award 2026

Daiichi Sankyo presented the O-Mamori Award 2026 in Berlin. Eight cardiology and oncology patient initiatives share 30,000 euros in prize money.

Gilead Extends Tender Offer for Arcellx

Gilead has extended its tender offer to acquire Arcellx until April 24, 2026. The offer remains $115 per share in cash plus a CVR.

IQVIA: German pharma market up in value in 2025, volumes slightly down

IQVIA reports 5.7% sales growth in Germany’s pharma market in 2025, while volumes slipped by 0.7%. In pharmacies, Rx grew faster than OTC.

Gilead to acquire Ouro Medicines for clinical BCMAxCD3 program

Gilead Sciences plans to buy Ouro Medicines for up to $2.175bn, adding OM336, a clinical BCMAxCD3 T cell engager for autoimmune diseases.

Hims & Hers shifts US weight loss strategy with Novo Nordisk deal

Hims & Hers is refocusing its US weight loss business and teaming up with Novo Nordisk, prioritizing access to a wider set of FDA-approved GLP-1 drugs.

Sandoz launches azelastine/fluticasone nasal spray in Germany and Switzerland

Sandoz has launched an azelastine/fluticasone nasal spray in Germany and Switzerland, expanding access to a fixed-dose allergy treatment option.

Sandoz partners with Samsung Bioepis on up to five biosimilars

Sandoz and Samsung Bioepis agreed to collaborate on up to five biosimilar assets, starting with an early-stage vedolizumab biosimilar program.

BC Partners and Bpifrance complete acquisition of Biogaran

BC Partners and Bpifrance have completed the acquisition of Biogaran from Servier. Erick Roche is set to become CEO by the end of March 2026.

Hikma reports revenue and core profit growth, launches buyback and reshuffles leadership

Hikma posted 2025 revenue and core profit growth, lifted its dividend and announced a US$250m share buyback plus immediate leadership changes.

Esperion to acquire Corstasis to add Enbumyst to its CV portfolio

Esperion has signed a definitive deal to acquire Corstasis. The transaction adds Enbumyst, an FDA-approved bumetanide nasal spray for edema.

BioMarin withdraws hemophilia gene therapy Roctavian

BioMarin is withdrawing Roctavian from the market after divestiture efforts failed, booking about $240M in Q4 2025 charges tied to the exit.

Novo Nordisk to invest €432m in Athlone manufacturing site

Novo Nordisk will invest €432m in its Athlone, Ireland, tabletting plant to add manufacturing capacity for current and future oral GLP-1 therapies.

GSK agrees to acquire 35Pharma, adding pulmonary hypertension asset HS235

GSK has agreed to acquire Canada’s 35Pharma for $950m in cash, gaining HS235, an activin signalling inhibitor being developed for pulmonary hypertension.

Novo Nordisk partners with Vivtex on oral biologics

Novo Nordisk and Vivtex will work on oral biologics for obesity and diabetes. Vivtex is eligible for up to US$2.1 billion plus tiered royalties.

Merck reshapes business ahead of Keytruda patent expiry

Merck & Co. is splitting operations into two divisions to prepare for Keytruda’s 2030 patent expiry and to broaden its portfolio.